Comparative Toxicovigilance of Capmatinib and Tepotinib in NSCLC: Respiratory Signal Detection and Adverse Event Profiling via FAERS
Journal of Biochemical and Molecular Toxicology · 2026
DOI: 10.1002/jbt.70657 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2026. Verfasst von Xing Chang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Medical Center of Soochow University, Suzho…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pyrimidines, Piperidines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Suzhou Area Science and Technology Special Program for Innovation-Driven Biopharmaceutical Industrial Chain Enhancement, Suzhou Medical College-QiLu Medical Research Program of Soochow University, Gusu Talent Program.
Abstract (Originalsprache)
Capmatinib and tepotinib are selective MET inhibitors for MET exon 14 skipping non‐small cell lung cancer (NSCLC), yet comprehensive real‐world safety profiles, particularly concerning respiratory and rare adverse events (AEs), remain limited. We conducted a disproportionality analysis of the FDA AE Reporting System (FAERS) database, utilizing four algorithms (ROR, PRR, BCPNN, MGPS) to identify AE signals from 1771 cases for capmatinib and 470 for tepotinib, standardized with MedDRA v26.0. Both inhibitors shared signals for systemic AEs, such as peripheral oedema and gastrointestinal disorders. However, their respiratory AE profiles diverged: capmatinib was associated with pleural effusion and pulmonary oedema, whereas tepotinib was linked to infectious complications, including interstitial lung disease and infectious pleural effusion. Importantly, we identified significant novel signals beyond current drug labels: sensory disturbances, and thrombosis for capmatinib; and fluid imbalance‐related events for tepotinib. These distinct AE profiles highlight an infection‐driven pulmonary risk for tepotinib requiring close monitoring, while capmatinib's association with sensory disorders warrants specific patient management considerations. Our findings underscore the need for individualized safety monitoring based on the unique AE profiles of each MET inhibitor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Medical Center of Soochow University, Suzhou, China.
- Department of Pharmacy, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, China.
ORCID-Profile: Xing Chang
Förderung
- Suzhou Area Science and Technology Special Program for Innovation-Driven Biopharmaceutical Industrial Chain Enhancement
- Suzhou Medical College-QiLu Medical Research Program of Soochow University
- Gusu Talent Program
- Suzhou Industrial Park Healthcare Talent Support Initiative
Zitieren
APA
Chang, X., Shao, D., Bao, J., Liu, Z., & Ma, J. (2026). Comparative Toxicovigilance of Capmatinib and Tepotinib in NSCLC: Respiratory Signal Detection and Adverse Event Profiling via FAERS. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.70657
Vancouver
Chang X, Shao D, Bao J, Liu Z, Ma J. Comparative Toxicovigilance of Capmatinib and Tepotinib in NSCLC: Respiratory Signal Detection and Adverse Event Profiling via FAERS. Journal of Biochemical and Molecular Toxicology. 2026. doi:10.1002/jbt.70657
BibTeX
@article{Chang2026,
author = {Chang, Xing and Shao, Danyan and Bao, Jianan and Liu, Zi and Ma, Jingjing},
title = {Comparative Toxicovigilance of Capmatinib and Tepotinib in NSCLC: Respiratory Signal Detection and Adverse Event Profiling via FAERS},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2026},
doi = {10.1002/jbt.70657}
}
EUVIMED